A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada
Authors:
- Carissa BeaulieuCBCarissa Beaulieu
- Arthur LuiALArthur Lui
- Dimas YusufDYDimas Yusuf
- Zainab AbdelazizZAZainab Abdelaziz
- Brock RandolphBRBrock Randolph
- Eugene BatuyongEBEugene Batuyong
- Sunita GhoshSGSunita Ghosh
- Oliver F. BatheOBOliver F. Bathe
- Vincent TamVTVincent Tam
- Jennifer L. SpratlinJSJennifer L. Spratlin
Open Access
- 13 January 2021
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 417-427
Abstract
Background: Biliary tract cancers (BTC) are uncommon malignancies and are underrepresented in the literature. Methods: We performed a retrospective population-based review of adult patients with biopsy-confirmed BTC in Alberta from 2000 to 2015. Demographic data, risk factors, symptoms, treatment, and staging data were collected and analyzed. Survival analyses were completed. Results: A total of 1604 patients were included in our study, of which 766 (47.8%) were male. The median age at diagnosis was 68 (range 19–99). There were 374 (23.3%) patients with resectable tumors at diagnosis versus 597 (37.2%) with unresectable tumors. Of the patients, 380 (21.5%) received chemotherapy (CT) and 81 (5.0%) underwent radiation therapy. There was a clear trend with worsening stage and performance status associated with shorter median overall survival (OS). Ampulla of Vater tumors had the best median OS (25.69 months), while intrahepatic bile duct cancers had the worst (5.78 months). First-line palliative CT regimens included gemcitabine+cisplatin (OS 14.98 months (mo), n = 212), single agent gemcitabine (OS 12.42 mo, n = 22), capecitabine (OS 8.12 mo, n = 8), and capecitabine+gemcitabine (OS 6.93 mo, n = 13). Patients with advanced or metastatic disease who received first-line gemcitabine+cisplatin had a median OS of 11.8 months (n = 119). Conclusion: BTCs have poor survival. Worse outcomes occur in higher stage and poorer Eastern Cooperative Oncology Group (ECOG) performance status patients across all tumor subtypes. Tumor resectability at diagnosis was associated with better OS. Our study supports the use of gemcitabine+cisplatin as a combination first-line palliative CT, as patients treated in Alberta have a comparable OS to that reported in the ABC-02 phase III study.Keywords
This publication has 14 references indexed in Scilit:
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Epidemiology of biliary tract cancers: an updateAnnals of Oncology, 2008
- Cholangiocarcinoma: lessons from ThailandCurrent Opinion in Gastroenterology, 2008
- Systemic Therapy for Biliary Tract CancersThe Oncologist, 2008
- CholangiocarcinomaClinics in Liver Disease, 2008
- Diagnosis and Surgical Management of Gallbladder Cancer: A ReviewJournal of Gastrointestinal Surgery, 2007
- CholangiocarcinomaThe Lancet, 2005
- Biliary tract neoplasms: update 2003Current Opinion in Oncology, 2004
- Epidemiology and Molecular Pathology of Gallbladder CancerCA: A Cancer Journal for Clinicians, 2001
- Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United StatesHepatology, 2001